Cardiac norepinephrine release: Modulation by ovariectomy and estrogen

Experimental Biology and Medicine

Volumn 228, Issue 2, 2003, Pages 194-199

  Eskin, Bernard A ^a   Snyder, David L ^b   Roberts, Jay ^a   Aloyo, Vincent J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Cardiac norepinephrine release; Cardiac synaptosomes; Cardiovascular disease; Long term estrogen replacement; Ovariectomy

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN THERAPY; HEART MUSCLE CELL; HEART NERVE; HEART PROTECTION; MEMBRANE DEPOLARIZATION; NONHUMAN; NORADRENALIN RELEASE; OVARIECTOMY; POSTMENOPAUSE; RAT; SYNAPTIC TRANSMISSION; SYNAPTOSOME;

ANIMALIA; EQUIDAE;

EID: 0037315917     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020322800210     Document Type: Article

References (35)

1. Chow M. Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. J Clin Pharmacol 35:11S-17S, 1995.
2. Barrett-Connor E. Epidemiology and the menopause: a global overview. Int J Fertil Menopausal Study 38(Suppl 1):6-14, 1993.
3. Barrett-Connor E. Postmenopausal estrogen and heart disease. Atherosclerosis 118:S7-S10, 1995.
4. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M. Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1775, 1997.
5. Col NF, Eckman MH, Karas RH, Paukder SG, Goldberg RJ, Ross EM, Orr RK, Wong JB. Patient-specific decisions about hormone replacement therapy in post-menopausal women. J Am Med Assoc 277:1140-1147, 1997.
6. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 38:199-210, 1995.
7. Martino M, Eskin BA. Estrogen and the postmenopausal heart. Female Patient 24:19-28, 1999.
8. Subbiah MTR. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med 217:23-29, 1998.
9. Hulley S, Grady D, Bush T, Fineberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 280:608-613, 1998.
10. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. HERS research group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). J Am Med Assoc 288:49-57, 2002.
11. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA. Snyder TE, Furberg CD. Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522-529, 2000.
12. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19:61-109, 1998.
13. Writing Group for the Women's Health Initiative (WHI) Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from WHI randomized controlled trial. J Am Med Assoc 288:321-333, 2002.
14. Griffin M, Lee HW, Zhao L, Eghbali-Webb M. Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: effects of estrogen. Mol Cell Biochem 215:21-30, 2000.
15. Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 416:107-112, 1997.
16. Jankowski M, Rachelska G, Donghao W, McCann SM, Gutkowska J. Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc Natl Acad Sci U S A 98:11765-11770, 2001.
17. Johnson BD, Zheng W, Korach KS, Scheuer T, Catterall WA, Rubanyi GM. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J Gen Physiol 110:135-140, 1997.
18. Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA, Katzenellenbogen BS, Meyer R, Vetter H, Grohe C. Activation of estrogen receptor-Β is a prerequisite for estrogen-dependent up-regulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett 502:103-108, 2001.
19. Dubey RK, Jackson EK, Cardiovascular protective effects of 17Β-estradiol metabolites. J Applied Physiol 91:1868-1883, 2001.
20. Boddi M, Coppo M, Padeletti L, Michelucci A, Gensini GF, Poggesi L, Neri Serneri GG. Enhanced cardiac norepinephrine release in patients with idiopathic ventricular tachycardia related to the occurrence of arrhythmias. Am Heart J 127:686-689, 1994.
21. Raiteri L, Raiteri M. Synaptosomes still viable after 25 years of superfusion. Neurochem Res 25:1265-1274, 2000,
22. Aloyo VJ, McIlvain HB, Bhavsar VH, Roberts J. Characterization of norepinephrine accumulation by a crude synaptosomal-mitochondrial fraction isolated from rat heart. Life Sci 48:1317-1324, 1991.
23. Snyder DL, Johnson MD, Aloyo V, Eskin B, Roberts J. Age-related changes in cardiac norepinephrine release: role of calcium movement. J Gerontol Biol Sci 50A:B358-B367, 1995.
24. Snyder DL, Aloyo VJ, Mcllvain HB, Johnson MD, Roberts J. Effect of age on potassium- and tyramine-induced release of norepinephrine from cardiac synaptosomes in male F344 rats. J Gerontol Biol Sci 47:B190-B197, 1992.
25. Snyder DL, Johnson MD, Eskin BA, Wang W, Roberts J. Effect of age on cardiac norepinephrine release in the female rat. Aging Clin Exp Res 7:210-217, 1995.
26. Grollman A. Essentials of Endocrinology (2nd ed). Philadelphia: JP Lippincott Company, pp507-509, 1947.
27. Opie LH, Walpoth B, Barsacchi R. Calcium and catecholamines: relevance to cardiomyopathies and significance in therapeutic strategies. J Mol Cell Cardiol 17(Suppl 2):21-34, 1985.
28. Downing SE, Lee JC. Contribution of α-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy. Circ Res 52:471-478, 1983.
29. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 17:291-306, 1985.
30. Schomig A, Dart A, Dietz R, Mayer E, Kubler W. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: locally mediated release. Circ Res 55:689-701, 1984.
31. Schomig A, Haass M, Richardt G. Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J 12(Suppl F):38-47, 1991.
32. Richardt G, Waas W, Kranzhofer R, Cheng B, Lohse MJ, Schomig A. Interaction between the release of adenosine and noradrenaline during sympathetic stimulation: a feedback mechanism in the rat heart. J Mol Cell Cardiol 21:269-277, 1989.
33. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 60:1390-1397, 1982.
34. Esler M. Kaye D, Thompson J, Jennings G, Cox H, Turner A, Lambert G, Seals D. Effects of aging on epinephrine secretion and regional release of epinephrine from the human heart. J Clin Endocrin Metab 80:435-442, 1995.
35. Eisenhoffer G. Esler M, Meredith I, Dart A, Cannon RO, Quyyumi A, Lambert G, Chin J, Jennings G, Goldstein D. Sympathetic nervous function in human heart as assessed by cardiac spillover of dihydroxyphenylglycol and norepinephrine. Circulation 85:1775-1785, 1992.